Mirtazapin Amarox (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, increasing the release of norepinephrine and serotonin. It also antagonises 5‑HT2 and 5‑HT3 receptors while partially agonising 5‑HT1A receptors, which together enhance serotonergic activity and produce an antidepressant effect.

The appropriate dose of Mirtazapin Amarox is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for mirtazapine in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It is excreted in breast milk, so clinicians should evaluate the potential benefits against possible risks to the infant before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapin Amarox (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined α2‑adrenergic antagonism and serotonergic receptor profile. This results in a distinct side‑effect pattern, such as higher sedation and appetite stimulation, which may be advantageous for patients with insomnia or weight loss.

Store Mirtazapin Amarox at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Mirtazapin Amarox is taken orally, usually once daily in the evening to minimise daytime sedation. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis or severe neutropenia, seizures, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, unexplained fever, or severe skin reactions and seek immediate medical attention if they occur.

Mirtazapin Amarox is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently receiving monoamine oxidase inhibitors (MAOIs) or who have taken an MAOI within the past 14 days. Caution is also advised for individuals with severe hepatic impairment.